Ceftibuten
- Atc Codes:J01DD14
- CAS Codes:97519-39-6
- PHARMGKB ID:97519-39-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Bulgaria: Cedax; Germany: Caedax, Keimax; Greece: Caedax; Hungary: Cedax; Italy: Cedax, Isocef; Netherlands: Cedax; Poland: Cedax; Portugal: Caedax; Romania: Cedax; Slovakia: Cedax; Slovenia: Cedax; Spain: Cedax; Sweden: Cedax.
North America
USA: Cedax.
Latin America
Mexico: Cedax.
Asia
Japan: Seftem.
Drug combinations
Chemistry
Ceftibuten: C~15~H~14~N~4~O~6~S~2~. Mw: 410.42. (1) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl]amino]-8-oxo-, [6R-[6α,7β(Z)]]-; (2)(+)-(6R,7R)-7-[(Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. CAS-97519-39-6 (1989).
Pharmacologic Category
Antibacterials; Third Generation Cephalosporins. (ATC-Code: J01DD14).
Mechanism of action
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins. Usually bactericidal. Active in vitro and in clinical infections against Gram-positive aerobic bacteria, such as Streptococcus pneumoniae (penicillin-susceptible strains only) and S. pyogenes (group A β-hemolytic streptococci). Active in vitro and in clinical infections against Gram-negative aerobic bacteria such as Haemophilus influenzae (including β-lactamase-producing strains) and Moraxella catarrhalis (including β-lactamase-producing strains). Inactive against Pseudomonas aeruginosa. Active in vitro against anaerobes such as Bacteroides; many strains of B. fragilis are resistant. Also active in vitro against Clostridium (except C. difficile), Peptococcus, and Peptostreptococcus. Inactive against fungi and viruses.
Therapeutic use
Bronchitis, otitis media, and pharyngitis/tonsillitis due to H. influenzae and M. catarrhalis, both β-lactamase-producing and nonproducing strains, as well as S. pneumoniae (weak) and S. pyogenes.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. It is not known if ceftibuten crosses the placenta (other cephalosporins cross the placenta and are considered safe for use during pregnancy). Excretion in breast milk unknown (use caution).
Unlabeled use
Acute maxillary sinusitis caused by susceptible S. pneumoniae, H. influenzae, or M. catarrhalis. Acute bronchitis, bronchiectasis, or pneumonia caused by susceptible bacteria. Urinary tract infections.
Contraindications
Hypersensitivity to ceftibuten, any component of the formulation, or other cephalosporins.
Warnings and precautions
Use with caution in history of penicillin allergy, especially IgE-mediated reactions (e.g. anaphylaxis, angioedema, urticaria). Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in renal impairment. May cause positive direct Coombs’ test, false-positive urinary glucose test using cupric sulfate, false-positive serum or urine creatinine with Jaffé reaction.